|
"A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition tothe Paliperidone Palmitate 3-Month Formulation in Patients with SchizophreniaPreviously Stabilized on the Paliperidone Palmitate 1-Month Formulation"
|
Ongoing
|
paliperidone
|
3
|
R092670SCH3015
|
Jeddah psychiatric hospital, Al-Amal Complex for mental health (Dammam)
|
|
"A Randomized controlled Trial of Influenza Vaccineto Reduce Adverse Vascular Events"
|
Ongoing
|
Vaxigrip
|
3
|
version 2
|
King Khalid University Hospital (Riyadh), King Abdulaziz University Hospital (Jeddah), King Fahad Medical City (Riyadh), Madinah Cardiac Center
|
|
"Study H9X-MC-GBGC is a Phase 3, randomized, double-blind, placebo-controlled trial withan open-label extension that investigates the effect of the addition of dulaglutide (0.75 and1.5 mg/week) or placebo weekly to metformin and/or basal insulin on change from baselinein hemoglobin A1c at 26 weeks in children and adolescents with type 2 diabetes mellitus"
|
Ongoing
|
Dulaglutide 0.75 /1.5 mg
|
3
|
H9X-MC-GBGC
|
King Khalid University Hospital (Riyadh), International Medical Center (Jeddah)
|
|
RAINBOW study: a randomized, controlled study evaluating the efficacy and safety of Ranibizumab compared with laser therapy for the treatment of Infants BOrn prematurely With retinopathy of prematurity
|
Ongoing
|
Ranibizumab
|
3
|
CRFB002H2301 V 01
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
RAINBOW study: a randomized, controlled study evaluating the efficacy and safety of Ranibizumab compared with laser therapy for the treatment of Infants BOrn prematurely With retinopathy of prematurity
|
Ongoing
|
Ranibizumab
|
3
|
CRFB002H2301 V 01
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
|
Terminated
|
NIVOLUMAB/IPILIMUMAb
|
3
|
CA209-227
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
Phase 2 study of 5 Days azacytidine priming prior to fludarabine, cytarabine and G-CSF combination for patients with relapsed or refractory AML.
|
Ongoing
|
Vidaza
|
2
|
Version 1.1
|
King Fahad Medical City (Riyadh)
|
|
"A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety ofAbatacept SC in Combination with Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults with Early Rheumatoid Arthritis who are Methotrexate Naive"
|
Terminated
|
Abatacept
|
3b
|
IM101550
|
King Fahad Medical City (Riyadh)
|
|
Asia and Latin America Fracture Observational Study
|
Ongoing
|
Forteo (teriparatide)
|
4
|
B3D-MC-B02
|
King Fahad Medical City (Riyadh), Al-Noor Specialist Hospital, King Fahad Hospital (Jeddah), Sabia General Hospital, King Saud Medical City (Riyadh), King Fahad University Hospital (Al-Khobar)
|
|
An Open-label, Baseline-controlled, Multicenter, Phase 3 Dose-titration Study Followed by a Fixed-dose Observation Period to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Children and Adolescents from 5 to less than 18 Years of Age with Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)
|
Rejected
|
Mirabegron
|
3
|
178-CL-206A
|
N\A
|
